Search
Probenecid
go.drugbank.com/drugs/DB01032ApprovedInvestigationalThe prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. … Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
Turoctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalThe essential difference between turoctocog alfa and N8-GP, however, is the specific attachment of a 40-kDa polyethylene glycol (PEG) group to a specific _O_-glycan in the truncated B-domain of the general … Fundamentally, the N8-GP moiety is identical to [turoctocog alfa], a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the
Products: ESPEROCT 500 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, ESPEROCT 1000 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADETEluxadoline
go.drugbank.com/drugs/DB09272ApprovedInvestigationalThe mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. … of abdominal pain and reductions in the Bristol Stool Scale.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigational[L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed … [L39739] On March 22, 2022, the marketing authorization of sotagliflozin for the treatment of type 1 diabetes mellitus was withdrawn by the EMA due to commercial reasons.
Pargyline
go.drugbank.com/drugs/DB01626ApprovedPargyline is a monoamine oxidase inhibitor with antihypertensive properties.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDexbrompheniramine
go.drugbank.com/drugs/DB00405ApprovedDexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
Mixtures: Alahist PE, Ala-hist PEPromethazine
go.drugbank.com/drugs/DB01069ApprovedInvestigational[A189901] Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.
Mixtures: COPHADYL-E COUGH LINCTUSCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePhenytoin
go.drugbank.com/drugs/DB00252ApprovedInvestigationalVet approved[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal … [A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market.[A189219]
Products: FENIFFLER-T, EPAMIN ® XR 100 MG CÁPSULAS DE LIBERACIÓN PROLONGADAThrombin alfa
go.drugbank.com/drugs/DB11572Approvedapproved by certain organizations like the European Medicines Agency [L2079]. … The cell line used to manufacture Thrombin Alfa has been tested and shown to be free of known infectious agents.
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigationalto its predecessors. … [A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative